Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.35 |
| ▸ | APLNR | P35414 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
| ▸ | RELA | Q04206 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9176523 | 0.98 | CA1 (0.40) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL29422137 | 0.93 | CA12 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL1927273 | 0.88 | DGAT1 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28763660 | 0.88 | DGAT1 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL18345387 | 0.83 | DGAT1 (0.39) | CA1CA2TDP1DGAT1CA7 | |
| SCHEMBL5795897 | 0.83 | DGAT1 (0.39) | CA1CA2TDP1DGAT1CA7 | |
| SCHEMBL28026126 | 0.83 | CA12 (0.41) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL28672370 | 0.81 | CA1 (0.40) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL19931568 | 0.81 | ALDH1A1 (0.44) | CA12CA1CA2CA9TDP1 | |
| SCHEMBL874509 | 0.81 | CA12 (0.41) | CA12CA1CA2CA9TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151258-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2019-05-23 | — | — | US | claimed |
| EP-2694047-B1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME | US HEALTH (US) | 2018-11-28 | — | — | EP | claimed |
| US-20170367998-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME | THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES | 2017-12-28 | — | — | US | claimed |
| US-9629816-B2 | Small molecule therapeutic compounds targeting thioesterase deficiency disorders and methods of using the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2017-04-25 | — | — | US | claimed |
| US-20140148513-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME | DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-05-29 | — | — | US | claimed |
| EP-2694047-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME | The U.S.A. as represented by the Secretary, Department of Health and Human Services (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012139119-A1 | SMALL MOLECULE THERAPEUTIC COMPOUNDS TARGETING THIOESTERASE DEFICIENCY DISORDERS AND METHODS OF USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-10-11 | — | — | WO | claimed |
| US-20100093817-A1 | Compounds | BIAL - PORTELA & CA S.A. (PT) | 2010-04-15 | — | — | US | claimed |
| EP-2121668-A2 | 6,8-DICHLORCHROMAN-3-YL-1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL - Portela & Ca., S.A. (PT) | 2009-11-25 | — | — | EP | claimed |
| WO-2008094054-A2 | 6, 8-DICHLORCHROMAN-3-YL-L, 3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | BIAL-PORTELA & CA, S.A. (PT) | 2008-08-07 | — | — | WO | claimed |
| US-6132499-A | Inks | XEROX CORPORATION (US) | 2000-10-17 | — | — | US | claimed |
| US-6110265-A | Ink compositions | XEROX CORPORATION (US) | 2000-08-29 | — | — | US | claimed |
| US-6106601-A | MIXTURE CONTAINING OXAZOLINE AND THIOUREA COMPOUNDS | XEROX CORPORATION (US) | 2000-08-22 | — | — | US | claimed |
| US-6071333-A | Ink compositions | XEROX CORPORATION (US) | 2000-06-06 | — | — | US | claimed |
| US-6045607-A | FIRST AND SECOND SOLID CARBAMATES WITH A DISSIMILAR MELTING POINTS; LIGHTFASTNESS COMPONENT; A LIGHTFASTNESS ANTIOXIDANTS, AND A COLORANT; USEFUL FOR ACOUSTIC INK PRINTING | XEROX CORPORATION (US) | 2000-04-04 | — | — | US | claimed |
| EP-0763012-B1 | SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS | BRITISH BIOTECH PHARM (GB) | 1999-06-09 | — | — | EP | claimed |
| EP-0534347-B1 | A method for the preparation of N-ethylhydroxylamine hydrochloride | HOECHST ROUSSEL PHARMA (US) | 1995-06-28 | — | — | EP | claimed |
| US-5206406-A | Method for the preparation of N-ethylhydroxylamine hydrochloride | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-04-27 | — | — | US | claimed |
| EP-0522000-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-13 | — | — | EP | claimed |
| WO-1991014674-A2 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093817-A1 | Compounds | TPMT, CYP2C8, ABL1 | CA12 2632/4885CA1 3237/4885CA2 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.